ストックスクリーナーアプリを入手
1.18
0.85%
0.01
アフターアワーズ：
1.27
0.09
+7.63%
Telomir Pharmaceuticals Inc (TELO) 最新ニュース
Telomir Pharmaceuticals targets global partnerships after FDA clearance for Telomir-Zn - Traders Union
Telomir Pharmaceuticals scientific advisor named plenary lecturer at Tokyo women health event - Traders Union
Experimental drug found to slow bone cancer cell growth in dog and human lab tests - DVM360
Telomir announces preclinical study on AMD treatment candidate - Investing.com
Telomir announces preclinical study on AMD treatment candidate By Investing.com - Investing.com Nigeria
Telomir-Zn Preclinical Data Highlight Retinal Regeneration Potential - TipRanks
Vision gains in fish study link Telomir (NASDAQ: TELO) eye data to its cancer program - Stock Titan
Maxim Group Initiates Telomir Pharmaceuticals(TELO.US) With Buy Rating, Announces Target Price $4 - Moomoo
Telomir Announces Peer-Reviewed Publication Showing - GlobeNewswire
Telomir (TELO) investors approve all 2026 votes - Stock Titan
Form 8K Telomir Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com Nigeria
Telomir unveils new preclinical data for Telomir-Zn - TipRanks
Telomir Pharmaceuticals Announces Research Demonstrating In-Vitro Anti-Cancer Activity Of Telomir-Zn In Human And Canine Osteosarcoma Models - marketscreener.com
Telomir Announces Research with The Ohio State University - GlobeNewswire
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Telomir Pharmaceuticals (TELO) Climbs 3.81% as Micro-Cap Biotech Momentum BuildsMomentum Surge Alerts - siam.in
Telomir Pharmaceuticals (TELO): John Paul DeJoria reports 5.169% ownership stake - Stock Titan
TELO Q4 2025 Earnings: Deep EPS Miss Underscores Pre-Revenue ChallengesFinancial Data - vinanet.vn
Telomir Flags Substantial Doubt About Ability to Continue as Going Concern - Minichart
Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results - MarketBeat
Telomir Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Telomir-Zn shows promise for iron-addicted cancers - BioWorld News
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4%Should You Sell? - MarketBeat
Telomir-Zn Preclinical Data Support Advancement in TNBC - TipRanks
Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models - Quiver Quantitative
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models - Yahoo Finance
Telomir Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez - Moomoo
Telomir Pharmaceuticals (TELO) Slides 3.4% to $1.21 as Key Support Level Comes into FocusCalendar Spread Trade - careplusvn.com
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Amid Pre-Revenue R&D Stage - dars.gov.et
Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ: TELO) Stock Price, News & Analysis - Kalkine
Telomir Pharmaceuticals (TELO) grants 50,000 stock options to director - Stock Titan
TELO|Telomir Pharmaceuticals Inc|Price:1.230|Chg%:+0.080 - TradingKey
Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34 - Stock Titan
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Telomir Pharmaceuticals Inc (TELO) Cash Flow - TradingKey
Telomir Pharmaceuticals Inc (TELO) Balance Sheet - TradingKey
Telomir Pharmaceuticals Inc (TELO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Telomir Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Income Statement - TradingKey
Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
12 Health Care Stocks Moving In Tuesday's Intraday Session - Sahm
TELO Q4 2025 Earnings: Wider-than-Expected Loss Amid Early-Stage Drug DevelopmentSaaS Earnings Trends - vinanet.vn
TELO Q4 2025 Earnings: Wider-than-Expected Loss but Stock Surges 17.5% Amid Strategic ProgressForward EPS Estimate - dars.gov.et
Andriy Mushak Net Worth (2026) - GuruFocus
TELO Q4 2025 Earnings: EPS Misses Estimates Markedly, No Revenue YetConsensus Miss Rate - careplusvn.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
TELO Q4 2025 Earnings: EPS Misses Estimates by Wide Margin as Pre-Revenue Biotech Reports No RevenueEarnings Power Value - DonanımHaber
Number of shareholders of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals (TELO) Slips 2.3% as Stock Tests Key Support LevelThematic ETF Flow - dars.gov.et
Price to earnings forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TELO) - TradingView
TELO Q4 2025 Earnings: Wider-Than-Expected Loss Reflects R&D InvestmentWeak Earnings Momentum - DonanımHaber
Price to sales forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Price to book forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Enterprise value to EBITDA forward of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Telomir Pharmaceuticals, Inc. develops Telomir-Zn to target intracellular metal balance in cancer cells - Traders Union
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model - ACCESS Newswire
Telomir Pharmaceuticals Q4 2025 Earnings: EPS Misses Estimates Amid Pre-Revenue Development StageEPS Revision Trend - dars.gov.et
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):